- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia2020 | Central Library of Charles University
- Treatment of Chronic Lymphocytic Leukemia with TP53 Aberrations2015 | Faculty of Medicine in Pilsen
- Single-agent ibrutinib in RESONATE-2TM and RESONATETM versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia2019 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové